NuCana Corp - Rasio nilai perusahaan marang dodolan NCNA

Simbol resmi perusahaan NuCana PLC (NCNA)

How can the fight against tumor resistance be monetized through nucleoside drugs? This EV/Sales multiple chart demonstrates current dynamics, where the indicator reaches 0.00. Experienced scientists and top managers ensure capital efficiency. Meanwhile, ProTides patent protection and strict FDA oversight create a sustainable barrier for competitors, securing the monopoly status of NuCana plc (NCNA) intellectual property.

NuCana (NCNA): Nilai perusahaan marang pendapatan saka 23.11.2025 nganti 20.11.2026

NuCana - rincian analitis lan metrik utama (NCNA)

- rega lan prakiraan konsensus rega:
- data saldo dhuwit lan arus kas:
Pambiji fundamental perusahaan:NCNA, NuCana Corp
Produk sing diprodhuksi nucana.com

The complex cryogenic logistics of biomaterials for NuCana plc (NCNA) require high capital expenditure, making the analysis of business value through the lens of revenue critically important. The dynamics of the EV/Sales market multiple reflect the current discount of future cash flows relative to sales volume, accounting for the debt load, which allows investors to identify asset overvaluation or the risks of a stagnation period in the company's fundamental value.

Analisis pesaing

Multiplikator nilai perusahaan marang pendapatan Incyte Corporation|HCM (HUTCHMED Corp) - Nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang dodolan Nuvation Pharma NUVB|Nilai perusahaan marang pendapatan DAWN|Multiplikator nilai perusahaan marang pendapatan Monopar Therapeutics MNPR|Nilai perusahaan marang pendapatan INBX (Inhibrx Biosciences)|IMAB (I-Mab Inc.) - Nilai bisnis marang pendapatan|Fennec Pharmaceuticals - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan HRTX (Heron Therapeutics Inc)|Nuvectis - Multiplikator EV/Sales|Nilai bisnis marang pendapatan CHRS (Coherus BioSciences Inc.)|CRBP: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Cardiff Oncology Corp (CRDF)|Rasio nilai perusahaan marang pendapatan BeyondSpring|BCAB: Nilai bisnis marang pendapatan|Multiplikator EV/Sales LIXT|Multiplikator EV/Sales Citius Pharmaceuticals Inc. (CTXR)|Rasio nilai perusahaan marang pendapatan Cellectar CLRB|BLRX (BioLineRx) - Nilai perusahaan marang volume dodolan|CANF: Nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan aprea.com|Kazia Therapeutics Limited (KZIA) - Rasio nilai perusahaan marang pendapatan|SLXN - Rasio total nilai perusahaan marang pendapatan|CMRX (Chimerix, Inc.) - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Cyclacel Pharmaceuticals CYCC|G1 Therapeutics Inc. (GTHX) - Nilai bisnis marang pendapatan|KRON - Multiplikator nilai perusahaan marang pendapatan|Kintara Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan ONCT (Oncternal)|Portage Biotech Corp - Multiplikator EV/Sales